Canada Life
XENE icon

Canada Life’s Xenon Pharmaceuticals XENE Stock Holding History

Canada Life’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$485K Buy
8,061
+1,037
+15% +$57.6K ﹤0.01% 1504
2026
Q1 		$411K Hold
7,024
– – ﹤0.01% 1528
2025
Q4 		$315K Hold
7,024
– – ﹤0.01% 1570
2025
Q3 		$274K Hold
7,024
– – ﹤0.01% 1672
2025
Q2 		$220K Hold
7,024
– – ﹤0.01% 1697
2025
Q1 		$236K Sell
7,024
-8,887
-56% -$337K ﹤0.01% 1709
2024
Q4 		$623K Hold
15,911
– – ﹤0.01% 1595
2024
Q3 		$628K Hold
15,911
– – ﹤0.01% 1632
2024
Q2 		$621K Buy
15,911
+5,879
+59% +$235K ﹤0.01% 1628
2024
Q1 		$432K Buy
10,032
+4,691
+88% +$216K ﹤0.01% 1718
2023
Q4 		$244K Buy
5,341
+848
+19% +$30K ﹤0.01% 1809
2023
Q3 		$153K Buy
4,493
+2,800
+165% +$105K ﹤0.01% 1895
2023
Q2 		$66K Sell
1,693
-699
-29% -$27.8K ﹤0.01% 1979
2023
Q1 		$86K Hold
2,392
– – ﹤0.01% 1996
2022
Q4 		$95K Hold
2,392
– – ﹤0.01% 1996
2022
Q3 		$86K Buy
2,392
+535
+29% +$19.2K ﹤0.01% 2015
2022
Q2 		$56K Hold
1,857
– – ﹤0.01% 2040
2022
Q1 		$60K Hold
1,857
– – ﹤0.01% 2114
2021
Q4 		$58K Buy
1,857
+753
+68% +$22.5K ﹤0.01% 2138
2021
Q3 		$17K Hold
1,104
– – ﹤0.01% 2469
2021
Q2 		$21K Sell
1,104
-1,313
-54% -$24.2K ﹤0.01% 2479
2021
Q1 		$43K Hold
2,417
– – ﹤0.01% 2337
2020
Q4 		$37K Hold
2,417
– – ﹤0.01% 2386
2020
Q3 		$27K Hold
2,417
– – ﹤0.01% 2365
2020
Q2 		$30K Buy
+2,417
New +$30.8K ﹤0.01% 2402

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Canada Life's XENE Position: Q2 2026 in Review

Canada Life increased its Xenon Pharmaceuticals (XENE) stake by 15% in Q2 2026, buying an estimated $57.6K and bringing the position to 8,061 shares worth $485K. The position accounts for ﹤0.01% of the portfolio, ranked #1504.

Canada Life first reported a position in XENE in Q2 2020 and has held it in 25 quarters since. The position peaked at $628K in Q3 2024. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Canada Life held 8,061 shares of Xenon Pharmaceuticals worth $485K as of Q2 2026.
  • Canada Life bought 1,037 Xenon Pharmaceuticals shares in Q2 2026, an estimated $57.6K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Canada Life's portfolio in Q2 2026, its #1504 holding.
  • Canada Life first reported a position in Xenon Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Canada Life's Xenon Pharmaceuticals position peaked at $628K in Q3 2024.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.